Kaloyan Tanev is a Psychiatry physician. ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
55 Fruit St
Warren 1220
Boston, MA 021142621
Telephone
617-726-7511Registry record last updated 8 Oct 2010.
Clinical trials
- Treating Sleep/Wake Cycle Disturbances in Basal Ganglia Disorders With Ramelteon
Sponsor: Massachusetts General Hospital
- Zolpidem CR and Hospitalized Patients With Dementia
Sponsor: Massachusetts General Hospital
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
92.1%Atypical Antipsychotic14.9%Risperidone44%Aripiprazole23%Olanzapine17%Quetiapine Fumarate17%Part D<11 patientsSSRI14.7%Escitalopram Oxalate34%Fluoxetine Hcl25%Trazodone Hcl22%Sertraline Hcl19%Part D<11 patients+ 13 more classes in this area
Cardiovascular
7.9%alpha-Adrenergic Blocker4.3%Prazosin Hcl100%Part D<11 patientsBeta blocker3.6%Propranolol Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2013–2024 per NIH RePORTER. The latest:
- Mismatch vs. standard intervention during memory reconsolidation blockade with propranolol: effect on psychophysiological reactivity during traumatic imagery
Massachusetts General Hospital
FY2024$167,500R21MH131987 - Mismatch vs. standard intervention during memory reconsolidation blockade with propranolol: effect on psychophysiological reactivity during traumatic imagery
Massachusetts General Hospital
FY2023$201,000R21MH131987 - Cognitive processing therapy for PTSD with co-morbid mild traumatic brain injury
Massachusetts General Hospital
FY2017$185,435K23MH097844
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Scheltens
Inserm
Rafael Tabarés‐Seisdedos
Universitat de València
Nick C. Fox
UK Dementia Research Institute
Perminder S. Sachdev
Department of Health and Aged Care
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”